• 5 min read
• Published on 14 October 2025
Listen to article
6:13Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
For as long as I can remember, the fight against Alzheimer's has felt like trying to solve a Rubik's Cube in the dark. The diagnostics were clunky, invasive, and eye-wateringly expensive. You practically had to remortgage your house for a PET scan, only to be told something you probably already suspected. It was a grim, inefficient business that left millions in a state of diagnostic limbo. But now, it seems someone has finally decided to turn the lights on.
The news that the FDA has approved a simple blood test for Alzheimer's is, to me, one of the most significant medical developments in years. Forget wonder drugs for a moment and think about the sheer practicality of it. We are moving from a world of specialist referrals and machinery the size of a small car to a simple blood draw at your local GP's office.
Roche and Eli Lilly’s Elecsys pTau181 test is the tool making this possible. It hunts for a specific protein in the blood that acts as a tell-tale sign of the disease. For years, this was the holy grail. Now, it’s a reality. This isn't just an incremental improvement. It’s a fundamental shift in how we approach the disease. It democratises diagnosis, taking it from the rarefied air of neurology clinics and placing it squarely in the hands of primary care physicians. The implications, frankly, are enormous.
Now, let’s put our investor hats on. What happens when you make something that was once difficult and expensive, suddenly easy and cheap? The market explodes. There are millions of people out there with early stage cognitive decline who were never going to get a PET scan. But a blood test during their annual check up? That’s a different story entirely.
This creates a tidal wave of newly diagnosed patients. For the pharmaceutical giants, this is the starting gun they’ve been waiting for. A larger, earlier-stage patient pool makes clinical trials more effective and, crucially, expands the commercial runway for any approved treatments. Eli Lilly has played a blinder here, positioning itself in both the diagnostic and therapeutic camps. It’s a classic case of selling the maps and the shovels for the gold rush you’re hoping to lead.
Of course, it’s not all champagne and ticker tape parades. A better diagnostic tool is wonderful, but it doesn’t magically create a cure. The history of Alzheimer's research is a graveyard of failed drugs and dashed hopes. Identifying patients earlier is a huge step, but it only increases the pressure to find treatments that actually work. The entire investment thesis hinges on this question of Early Alzheimer's Detection: Could Blood Tests Replace Scans?, and it's a theme worth exploring for anyone with a stomach for biotech.
Furthermore, while Lilly and Roche have the first-mover advantage, they won’t be alone for long. The scent of money is in the water, and competitors will be scrambling to get their own tests to market. This is a high stakes, high risk arena. Companies like Biogen and Cassava Sciences are also circling, hoping that a wider diagnostic net will catch more patients for their own therapeutic pipelines. Investing here requires a cool head and an acceptance that failure is always a possibility. This is not a game for the faint of heart.
View the full Basket:Early Alzheimer's Detection: Could Blood Tests Replace Scans?
View the full Basket:Early Alzheimer's Detection: Could Blood Tests Replace Scans?
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article